NSABP B-55 BIG 6-13

OlympiA: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Principal Investigator

Charles Geyer, MD

Status

Disease Site

Breast [BR] Breast

Phase

III

Developmental Therapeutics

No

Primary Objective

To assess the effect of adjuvant treatment with olaparib on Invasive Disease Free Survival (IDFS)

Patient Population

Patients with germline BRCA mutations and HER2-negative primary breast cancer who are at high risk of recurrence and who have completed definitive local treatment and systemic neoadjuvant or adjuvant chemotherapy.

Target Accrual

1800